Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer

Aaron Sulkes, Eliahu Gez, M. Raphael Pfeffer, Raphael Catane, Rut Isacson, Shoshana Biran

Research output: Contribution to journalArticlepeer-review


Thirty-six evaluable patients with metastatic measurable breast carcinoma previously treated with CMF or CMFVP were given second-line chemotherapy with Adriamycin, vinblastine, and mitomycin C (AVM), as follows: Adriamycin 20 mg/m2 and vinblastine 6 mg/m2 by i. v. push on days 1, 8, and 15, and mitomycin C 10 mg/m2 i. v. on day 1, every 6 weeks. Ten patients (28%) achieved partial remission (PR) lasting a median of 10 months, and eight patients (22%) experienced improvement of a lesser level than PR. An additional nine patients (25%) had disease stabilization; in the remaining nine patients (25%), persistent disease progression was observed. The median survival from the onset of AVM was 7 months for all patients; patients with PR survived a median of 13 months. Myelotoxicity was substantial and frequently interfered with the optimal administration of AVM, especially in patients with skeletal metastases; four patients were hospitalized with leukopenia and fever; all recovered promptly; one death was probably related to thrombocytopenia and CNS bleeding. Our results with AVM are similar to the average response rate published in the literature with the use of Adriamycin as a single agent in previously treated patients with advanced breast cancer.

Original languageEnglish
Pages (from-to)162-167
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Issue number2
StatePublished - Nov 1986
Externally publishedYes


Dive into the research topics of 'Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer'. Together they form a unique fingerprint.

Cite this